Company Overview and News


Add 0575
to your dashboard

Headline News

NAV & Investment in AgeX Therapeutics Inc.

2017-07-20 londonstockexchange
The unaudited Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2017 was 9.35 pence per share, including un-invested cash of £875,885. The portfolio is valued under IFRS at bid price.

Results for the Year ended 31 March 2017

2017-07-07 londonstockexchange
·      The Company acquired three investments in the year, including a significant investment in a Canadian medical marijuana company, and successfully disposed of one investment post year end. Further details of these investments are set out at in the Report of the Chief Executive Officer

Net Asset Value(s)

2017-04-12 londonstockexchange
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2017 was 10.56 pence per share, including un-invested cash of £3,285.  The portfolio is valued under IFRS at bid price.

Update on Potential Acquisition

2017-04-06 londonstockexchange
On 6 October 2016, the Board of Life Science Developments Limited (the "Company" or "LIFE") announced that it had signed a non-binding Term Sheet to acquire up to 100% of the issued share capital of The Diabetic Boot Company Limited ("DBC") for new shares in LIFE (the "Acquisition").

Half-year Report

2017-03-29 londonstockexchange
The Board of Port Erin, the AIM quoted company focused on investing in the biotechnology and

Net Asset Value(s)

2017-01-12 londonstockexchange
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2016 was 11.13 pence per share, including un-invested cash of £66,642.  The portfolio is valued under IFRS at bid price.

Half-year Report

2016-12-20 londonstockexchange
·      The Company has completed two investments during the period. Further details of these investments are set out at the Company's website and in the Co-Chairman's Statement in this report.

How Brazilian Resources' Strategy Translates To Upside Potential

2016-12-09 seekingalpha
Brazil Resources Inc. is undervalued at its current price, and has proven resources and real growth potential.

Regent Pacific mutates into selling pharmaceuticals to save sagging fortunes

2016-11-24 scmp
Company to begin selling Fortacin spray-on treatment for men’s premature ejaculation in Hong Kong by the end of 2017

Total Voting Rights

2016-05-04 londonstockexchange
Following the Placing as announced on 4 April 2016, the Company announces the following significant shareholdings in the Company's Ordinary Shares of 20 pence each (the "Ordinary Shares"):

Investee Company Update

2016-04-22 londonstockexchange
FastForward notes that its investee company, Diabetic Boot Company Limited ("DBC"), is seeking to raise up to £3.5 million from its shareholders by issuing new ordinary shares at a price of £23 per share. New shareholders will also receive warrants in the ratio of one warrant for each two new shares issued, the warrant is exercisable at £26.45 per share within five years ("Warrants"). The Company is not intending to invest in this issue.

Interim Results for the six months to 31 Dec 2015

2016-03-17 londonstockexchange
The Board of Port Erin, the AIM quoted company focused on investing in the biotechnology and

Expected timetable for suspension and de-listing

2016-02-11 londonstockexchange
Plethora Solutions Holdings PLC (AIM: PLE) would like to draw the attention of its shareholders to certain dates in the expected timetable of events set out in the scheme document published by the Company, as previously announced on 4 February 2016, in relation to the recommended acquisition of Plethora by Regent Pacific Group Limited (the "Scheme Document"). The Scheme Document is available on the Company's website at http://www.